Live better. A new health system to extend and enhance human life.
Joined April 2019
- Tweets858
- Following27
- Followers56.3K
- Likes1.2K
Leah’s acne wouldn’t clear up and she couldn’t figure out why.
Her doctor suspected PCOS, but after testing found no ovarian cysts, she wouldn’t order a hormone panel. She felt like she’d hit a dead end.
Then her Superpower results came back, and they pointed to a hormonal cause.
The results showed high levels of a hormone called DHEA-S (can contribute to acne).
She finally had something concrete to take back to her doctor. She left her next appointment with a PCOS diagnosis, a prescription, and an order for a follow-up hormone panel.
Superpower retweeted
NEW RESEARCH: Patients who switched from Zepbound injections to Lilly’s daily GLP-1 pill, Foundayo (orforglipron), maintained 75% of their weight loss after 52 weeks.
This could help solve one of the biggest problems with GLP-1s: weight regain.
Read more:
jnj.com/media-center/press-r…
BREAKING: A peptide pill helped keep psoriasis under control for 2 years, with at least 70% of patients assessed during long-term follow-up having clear or almost clear skin in a Phase 3 study.
Good News: The FDA has approved the first at-home treatment for thyroid eye disease, the condition that can slowly push the eyes forward out of their sockets.
Patients can now treat it with a shot at home.
BREAKING: FDA approves first functional cure for chronic Hepatitis B.
The cure is currently approved for patients without cirrhosis.
None of this is risk-free, but the trial results show the trade-off can be worth it.
And these tumors probably aren’t the only ones with a receptor a peptide can lock onto.
If researchers manage to find more, this approach could spread well beyond the gut and pancreas.
Some radiation still reaches healthy tissue, mainly the kidneys and bone marrow.
To protect the kidneys, patients get an infusion of amino acids, which compete with the drug for reabsorption there.
In FDA data, this cut the median kidney dose by 47%.
NETTER-1 only included people whose tumors were already growing. NETTER-2, reported in 2024, gave Lutathera as a first treatment instead.
With octreotide, it kept tumors from progressing for a median of 22.8 months, versus 8.5 on high-dose octreotide.
Those results led to FDA approval in 2018 for adults with certain receptor-positive neuroendocrine tumors of the gut and pancreas.
In 2024, the approval expanded to patients 12 and older.
Lutathera cut the risk of tumor progression or death by 79%.
At 20 months, 65.2% of people on Lutathera were alive with no tumor growth, compared with 10.8% on high-dose octreotide.
To test whether this peptide could slow tumor growth, the Phase 3 NETTER-1 trial enrolled 229 people with advanced neuroendocrine tumors that were already progressing.
They got either Lutathera or high-dose octreotide, a standard somatostatin-like drug.
The radiation also only travels at short distance.
Lutetium-177’s beta particles travel at most about 2 mm in tissue.
That’s far enough to reach nearby tumor cells, but short enough to limit how far the radiation spreads.
Once Lutathera binds to SSTR2, the cell pulls it inside.
Lutetium-177 then releases beta radiation, which is made of fast-moving electrons. It creates unstable molecules called free radicals that damage the targeted cell and cells immediately around it.
Lutathera makes this possible by linking DOTATATE to a cage-like molecule called DOTA, which holds lutetium-177 (a radioactive metal) in place.
Wherever the peptide finds SSTR2, it brings the radiation with it.
If a peptide could deliver enough radioactivity to make a tumor show up on a scan, then a stronger radioactive payload on the same peptide might be able to kill it.
